A153710 Stock Overview
Operates as a biomedical solution provider in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Optipharm.CO.,LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,530.00 |
| 52 Week High | ₩7,640.00 |
| 52 Week Low | ₩4,410.00 |
| Beta | 0.60 |
| 1 Month Change | -4.03% |
| 3 Month Change | -15.64% |
| 1 Year Change | -35.56% |
| 3 Year Change | -51.86% |
| 5 Year Change | -50.06% |
| Change since IPO | -61.28% |
Recent News & Updates
Health Check: How Prudently Does Optipharm.CO.LTD (KOSDAQ:153710) Use Debt?
Mar 30
What Kind Of Shareholders Hold The Majority In Optipharm.CO.,LTD's (KOSDAQ:153710) Shares?
Feb 23Should Optipharm.CO.LTD (KOSDAQ:153710) Be Disappointed With Their 52% Profit?
Jan 19
Recent updates
Health Check: How Prudently Does Optipharm.CO.LTD (KOSDAQ:153710) Use Debt?
Mar 30What Kind Of Shareholders Hold The Majority In Optipharm.CO.,LTD's (KOSDAQ:153710) Shares?
Feb 23Should Optipharm.CO.LTD (KOSDAQ:153710) Be Disappointed With Their 52% Profit?
Jan 19Optipharm.CO.LTD (KOSDAQ:153710) Has Debt But No Earnings; Should You Worry?
Dec 15Shareholder Returns
| A153710 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -6.3% | -2.3% | -1.9% |
| 1Y | -35.6% | 14.9% | -9.5% |
Return vs Industry: A153710 underperformed the KR Biotechs industry which returned 14.9% over the past year.
Return vs Market: A153710 underperformed the KR Market which returned -9.5% over the past year.
Price Volatility
| A153710 volatility | |
|---|---|
| A153710 Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A153710 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A153710's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | n/a | www.optipharm.co.kr |
Optipharm CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business.
Optipharm.CO.,LTD Fundamentals Summary
| A153710 fundamental statistics | |
|---|---|
| Market cap | ₩66.45b |
| Earnings (TTM) | -₩2.27b |
| Revenue (TTM) | ₩19.09b |
3.5x
P/S Ratio-29.3x
P/E RatioIs A153710 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A153710 income statement (TTM) | |
|---|---|
| Revenue | ₩19.09b |
| Cost of Revenue | ₩14.44b |
| Gross Profit | ₩4.64b |
| Other Expenses | ₩6.91b |
| Earnings | -₩2.27b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -154.65 |
| Gross Margin | 24.32% |
| Net Profit Margin | -11.89% |
| Debt/Equity Ratio | 46.3% |
How did A153710 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 21:47 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Optipharm.CO.,LTD is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kwan Jun Ra | NH Investment & Securities Co., Ltd. |